Then, to enable the therapeutic nanoagent to actively target the prostate tumor and enhance its cellular uptake efficiency, first, we modified the exterior surface of the liposome with AS1411 aptamer (Apt), which can specifically bind to nucleolin (NCL), a protein overexpressed on the plasma membrane of the prostate cancer. This evidence concerns the gene NUCLEOLIN and prostate carcinoma.